Bioton S.a.
BIO.WA
Get informed when a big investor buys or sells
+ FollowMarket Cap$330.58M
Close$
$7.28
89% upside
Current Fair Value
89% upsideUndervalued by 89% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $330.58 Million |
|---|---|
| Enterprise Value | $424.01 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.04 |
| Beta | 0.17 |
| Outstanding Shares | 85,864,200 |
Return
| Return on Equity | -1.44% |
|---|---|
| Return on Assets | -1.08% |
| Return on Invested Capital | 2.33% |
Valuation & Multiples
| P/E Ratio | -38.27 |
|---|---|
| PEG | 10 |
| Price to Sales | 1.93 |
| Price to Book Ratio | 0.64 |
| Enterprise Value to Revenue | 1.65 |
| Enterprise Value to EBIT | 28.32 |
| Enterprise Value to Net Income | -51 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$45.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$36.80 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bioton S.a.
361 employees
CEO: Jeremy Launders Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary f...